person · Reporting owner
Perceptive Xontogeny Venture Fund, LP
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Landos Biopharma, Inc.LABP · Entity 90644 | 10% owner | January 10, 2023 | January 11, 2023 |
| LianBioLIAN · Entity 9881 | Director · 10% owner | August 18, 2022 | August 22, 2022 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Director · 10% owner | February 19, 2025 | February 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Landos Biopharma, Inc.
Report date January 10, 2023 · Filed January 11, 2023
Jointly reported with PERCEPTIVE ADVISORS LLC, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, Perceptive Xontogeny Venture Fund II, LP, EDELMAN JOSEPH
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Pre-funded WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 | IndirectSee footnote | 27,272,727 |
Reported balance
After 2023-01-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-10 · Purchase · Acquired 27,272,727 · Balance 27,272,727 F1: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2: The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). The Advisor serves as the investment manager of PXV II, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. |
| Pre-funded WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 | IndirectSee footnote | 3,636,363 |
Reported balance
After 2023-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-10 · Purchase · Acquired 3,636,363 · Balance 3,636,363 F1: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F3: The securities are directly held by PX Venture (A), LLC ("PX Venture"). The Advisor serves as the investment manager of PX Venture, Mr. Edelman is the managing member of the Advisor. The Advisor, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
F2: The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). The Advisor serves as the investment manager of PXV II, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
F3: The securities are directly held by PX Venture (A), LLC ("PX Venture"). The Advisor serves as the investment manager of PX Venture, Mr. Edelman is the managing member of the Advisor. The Advisor, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
LianBio
Report date August 18, 2022 · Filed August 22, 2022
Jointly reported with PERCEPTIVE ADVISORS LLC, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, LEV LB Holdings, LP, C2 Life Sciences LLC, Perceptive Venture Advisors, LLC, LEV LB Holdings GP, LLC, EDELMAN JOSEPH
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | IndirectSee footnote | 3,728,491 |
Reported balance
After 2022-08-18 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-08-18 · Purchase · Acquired 998,240 · Balance 3,728,491 F5: Each American Depositary Share represents one Ordinary Share of the Issuer. F1: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 25,368,895 |
Reported balance
Holding disclosure · report date 2022-08-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,368,895 F1: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 21,653,385 |
Reported balance
Holding disclosure · report date 2022-08-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 21,653,385 F2: The securities are directly held by LEV LB Holdings, LP ("LEV LB"). LEV LB Holdings GP, LLC ("LEV LB LLC") is the manager of LEV LB. Mr. Edelman is the sole member of LEV LB LLC. LEV LB LLC and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 4,330,675 |
Reported balance
Holding disclosure · report date 2022-08-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 4,330,675 F3: The securities are directly held by Perceptive Xontogeny Venture Fund, LP ("Perceptive Xontogeny"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment advisor to Perceptive Xontogeny and is an affiliate of the Advisor. Joseph Edelman is the managing member of the Advisor. The Venture Advisor, the Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 2,477,005 |
Reported balance
Holding disclosure · report date 2022-08-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,477,005 F4: The securities are directly held by C2 Life Sciences LLC ("C2 Life"). The Advisor serves as the investment advisor to C2 Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
F2: The securities are directly held by LEV LB Holdings, LP ("LEV LB"). LEV LB Holdings GP, LLC ("LEV LB LLC") is the manager of LEV LB. Mr. Edelman is the sole member of LEV LB LLC. LEV LB LLC and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
F3: The securities are directly held by Perceptive Xontogeny Venture Fund, LP ("Perceptive Xontogeny"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment advisor to Perceptive Xontogeny and is an affiliate of the Advisor. Joseph Edelman is the managing member of the Advisor. The Venture Advisor, the Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
F4: The securities are directly held by C2 Life Sciences LLC ("C2 Life"). The Advisor serves as the investment advisor to C2 Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
F5: Each American Depositary Share represents one Ordinary Share of the Issuer.
Solid Biosciences Inc.
Report date February 19, 2025 · Filed February 21, 2025
Jointly reported with PERCEPTIVE ADVISORS LLC, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, EDELMAN JOSEPH
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 11,833,539 |
Reported balance
After 2025-02-19 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2025-02-19 · Purchase · Acquired 5,000,000 · Balance 11,833,539 F1: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager to the Master Fund. Mr. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 73,107 |
Reported balance
Holding disclosure · report date 2025-02-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 73,107 F2: The securities are directly held by Perceptive Xontogeny Venture Fund, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager to the Master Fund. Mr. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
F2: The securities are directly held by Perceptive Xontogeny Venture Fund, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Astria Therapeutics, Inc.
Report date February 01, 2024 · Filed February 05, 2024
Jointly reported with PERCEPTIVE ADVISORS LLC, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, EDELMAN JOSEPH
Section 16 reporting ended · disclosed 2021-02-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 4,873,721 |
Reported balance
After 2024-02-01 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2024-02-01 · Purchase · Acquired 2,481,350 · Balance 4,873,721 F1: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the :Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,611,699 |
Reported balance
Holding disclosure · report date 2024-02-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,611,699 F2: The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the :Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
F2: The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2025 Filed Feb 21, 2025 21:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | PurchaseCommon Stock | 5,000,000 | $4.03 | $20,150,000.00 |
DisclosureSEC source: 0001062993-25-003153 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,833,539 F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager to the Master Fund. Mr. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:02 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | PurchaseCommon Stock | 2,481,350 | $12.09 | $29,999,521.50 |
DisclosureSEC source: 0001062993-24-001979 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director EDELMAN JOSEPH · CIK 0001164426 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,873,721 F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the :Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| January 11, 2024 Filed Jan 12, 2024 22:15 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | PurchaseCommon Stock | 3,410,713 | $5.53 | $18,861,242.89 |
DisclosureSEC source: 0001062993-24-000843 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,833,539 F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager to the Master Fund. Mr. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 19:51 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | PurchaseCommon Stock | 740,000 | $6.20 | $4,588,000.00 |
DisclosureSEC source: 0001062993-23-023077 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director EDELMAN JOSEPH · CIK 0001164426 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,392,371 F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 20:11 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | PurchaseCommon Warrants (right to buy) · Derivative | 460,546 | $6.51 Strike: $8.03 | $2,999,996.64 |
DisclosureSEC source: 0001062993-23-019533 · form4.xml · derivative · entry 6 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director EDELMAN JOSEPH · CIK 0001164426 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 345,409 Underlying: Common Stock · 345,409 shares Expires not disclosed F1 · price: Represents the combined purchase price for each share of Common Stock and accompanying common warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on October 16, 2023. F5 · derivative.exercise_date: The common warrants are immediately exercisable and will expire on the fifth anniversary of their issuance, subject to the Beneficial Ownership Limitation (as defined below). Pursuant to the terms of the common warrants, the common warrant cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise. F5 · derivative.expiration_date: The common warrants are immediately exercisable and will expire on the fifth anniversary of their issuance, subject to the Beneficial Ownership Limitation (as defined below). Pursuant to the terms of the common warrants, the common warrant cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise. F4 · ownership.nature: The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 20:11 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | PurchasePre-funded Warrants (right to buy) · Derivative | 921,093 | $6.51 Strike: $0.00 | $5,999,078.71 |
DisclosureSEC source: 0001062993-23-019533 · form4.xml · derivative · entry 5 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director EDELMAN JOSEPH · CIK 0001164426 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 921,093 Underlying: Common Stock · 921,093 shares Expires not disclosed F2 · price: Represents the combined purchase price for each pre-funded warrant and accompanying common warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on October 16, 2023. F6 · derivative.exercise_date: The pre-funded warrants are immediately exercisable and will expire on the date they are exercised in full, subject to the Beneficial Ownership Limitation. F6 · derivative.expiration_date: The pre-funded warrants are immediately exercisable and will expire on the date they are exercised in full, subject to the Beneficial Ownership Limitation. F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 20:11 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | PurchaseCommon Warrants (right to buy) · Derivative | 921,093 | $6.51 Strike: $8.03 | $5,999,078.71 |
DisclosureSEC source: 0001062993-23-019533 · form4.xml · derivative · entry 4 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director EDELMAN JOSEPH · CIK 0001164426 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,151,366.25 Underlying: Common Stock · 690,819 shares Expires not disclosed F2 · price: Represents the combined purchase price for each pre-funded warrant and accompanying common warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on October 16, 2023. F5 · derivative.exercise_date: The common warrants are immediately exercisable and will expire on the fifth anniversary of their issuance, subject to the Beneficial Ownership Limitation (as defined below). Pursuant to the terms of the common warrants, the common warrant cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise. F5 · derivative.expiration_date: The common warrants are immediately exercisable and will expire on the fifth anniversary of their issuance, subject to the Beneficial Ownership Limitation (as defined below). Pursuant to the terms of the common warrants, the common warrant cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise. F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 20:11 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | PurchaseCommon Warrants (right to buy) · Derivative | 614,062 | $6.51 Strike: $8.03 | $3,999,999.87 |
DisclosureSEC source: 0001062993-23-019533 · form4.xml · derivative · entry 3 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director EDELMAN JOSEPH · CIK 0001164426 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 460,546 Underlying: Common Stock · 460,546 shares Expires not disclosed F1 · price: Represents the combined purchase price for each share of Common Stock and accompanying common warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on October 16, 2023. F5 · derivative.exercise_date: The common warrants are immediately exercisable and will expire on the fifth anniversary of their issuance, subject to the Beneficial Ownership Limitation (as defined below). Pursuant to the terms of the common warrants, the common warrant cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise. F5 · derivative.expiration_date: The common warrants are immediately exercisable and will expire on the fifth anniversary of their issuance, subject to the Beneficial Ownership Limitation (as defined below). Pursuant to the terms of the common warrants, the common warrant cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise. F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 20:11 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | PurchaseCommon Stock | 460,546 | $6.51 | $2,999,996.64 |
DisclosureSEC source: 0001062993-23-019533 · form4.xml · nonDerivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director EDELMAN JOSEPH · CIK 0001164426 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,611,699 F1 · price: Represents the combined purchase price for each share of Common Stock and accompanying common warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on October 16, 2023. F4 · ownership.nature: The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 20:11 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | PurchaseCommon Stock | 614,062 | $6.51 | $3,999,999.87 |
DisclosureSEC source: 0001062993-23-019533 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director EDELMAN JOSEPH · CIK 0001164426 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,652,371 F1 · price: Represents the combined purchase price for each share of Common Stock and accompanying common warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on October 16, 2023. F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 23:45 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | PurchasePre-funded Warrant · Derivative | 3,636,363 | $0.54 Strike: $0.01 | $1,963,636.02 |
DisclosureSEC source: 0001062993-23-000853 · form4.xml · derivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,636,363 Underlying: Common Stock · 3,636,363 shares Expires not disclosed F1 · derivative.exercise_date: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F1 · derivative.expiration_date: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F3 · ownership.nature: The securities are directly held by PX Venture (A), LLC ("PX Venture"). The Advisor serves as the investment manager of PX Venture, Mr. Edelman is the managing member of the Advisor. The Advisor, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 23:45 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | PurchasePre-funded Warrant · Derivative | 27,272,727 | $0.54 Strike: $0.01 | $14,727,272.58 |
DisclosureSEC source: 0001062993-23-000853 · form4.xml · derivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 27,272,727 Underlying: Common Stock · 27,272,727 shares Expires not disclosed F1 · derivative.exercise_date: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F1 · derivative.expiration_date: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). The Advisor serves as the investment manager of PXV II, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:52 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | PurchaseCommon Stock | 908,265 | $11.01 | $9,999,997.65 |
DisclosureSEC source: 0001062993-22-024291 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director EDELMAN JOSEPH · CIK 0001164426 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,038,309 F1 · balance_after: Reflects the Issuer's 6-to-1 reverse stock split effected on August 19, 2021. F2 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:41 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 73,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-023430 · form4.xml · nonDerivative · entry 3 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 73,107 F4 · price: Acquired pursuant to the acquisition by the Issuer of AavantiBio, Inc. ("AavantiBio") in exchange for shares of preferred stock of AavantiBio pursuant to the Agreement and Plan of Merger dated September 29, 2022. F5 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund, LP ("Perceptive Xontogeny"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment advisor to Perceptive Xontogeny and is an affiliate of the Advisor. Mr. Joseph Edelman is the managing member of the Advisor. The Venture Advisor, the Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:41 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 365,536 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-023430 · form4.xml · nonDerivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,422,826 F4 · price: Acquired pursuant to the acquisition by the Issuer of AavantiBio, Inc. ("AavantiBio") in exchange for shares of preferred stock of AavantiBio pursuant to the Agreement and Plan of Merger dated September 29, 2022. F2 · balance_after: Reflects the Issuer's reverse stock split that occurred on October 27, 2022. F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager to the Master Fund. Mr. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:41 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 2,163,120 | $7.05 | $15,249,996.00 |
DisclosureSEC source: 0001062993-22-023430 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,057,290 F1 · price: Acquired from the Issuer pursuant to the Securities Purchase Agreement dated September 29, 2022. F2 · balance_after: Reflects the Issuer's reverse stock split that occurred on October 27, 2022. F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager to the Master Fund. Mr. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 13:17 UTC | LianBio LIAN · Entity 9881 | PurchaseAmerican Depositary Shares | 998,240 | $2.40 | $2,395,776.00 |
DisclosureSEC source: 0001062993-22-018544 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner LEV LB Holdings, LP · CIK 0001789443 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner C2 Life Sciences LLC · CIK 0001890152 · Director · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,728,491 F5 · balance_after: Each American Depositary Share represents one Ordinary Share of the Issuer. F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 26, 2022 Filed May 27, 2022 14:06 UTC | LianBio LIAN · Entity 9881 | PurchaseAmerican Depositary Shares | 69,000 | $3.13 | $215,970.00 |
DisclosureSEC source: 0001062993-22-013616 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner LEV LB Holdings, LP · CIK 0001789443 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner C2 Life Sciences LLC · CIK 0001890152 · Director · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,730,251 F5 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.065 to $3.20, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range. F6 · balance_after: Each American Depositary Share represents one Ordinary Share of the Issuer. F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 25, 2022 Filed May 25, 2022 22:51 UTC | LianBio LIAN · Entity 9881 | PurchaseAmerican Depositary Shares | 120,000 | $2.63 | $315,600.00 |
DisclosureSEC source: 0001062993-22-013535 · form4.xml · nonDerivative · entry 3 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner LEV LB Holdings, LP · CIK 0001789443 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner C2 Life Sciences LLC · CIK 0001890152 · Director · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,661,251 F7 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.49 to $2.70, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range. F8 · balance_after: Each American Depositary Share represents one Ordinary Share of the Issuer. F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 24, 2022 Filed May 25, 2022 22:51 UTC | LianBio LIAN · Entity 9881 | PurchaseAmerican Depositary Shares | 42,551 | $2.47 | $105,100.97 |
DisclosureSEC source: 0001062993-22-013535 · form4.xml · nonDerivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner LEV LB Holdings, LP · CIK 0001789443 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner C2 Life Sciences LLC · CIK 0001890152 · Director · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,541,251 F6 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.36 to $2.53, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range. F8 · balance_after: Each American Depositary Share represents one Ordinary Share of the Issuer. F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 23, 2022 Filed May 25, 2022 22:51 UTC | LianBio LIAN · Entity 9881 | PurchaseAmerican Depositary Shares | 8,700 | $2.49 | $21,663.00 |
DisclosureSEC source: 0001062993-22-013535 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner LEV LB Holdings, LP · CIK 0001789443 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner C2 Life Sciences LLC · CIK 0001890152 · Director · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,498,700 F5 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.51, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range. F8 · balance_after: Each American Depositary Share represents one Ordinary Share of the Issuer. F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:59 UTC | LianBio LIAN · Entity 9881 | ConversionSeries A Preferred Shares · Derivative | 423,579 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042807 · doc4.xml · derivative · entry 12 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner LEV LB Holdings, LP · CIK 0001789443 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner C2 Life Sciences LLC · CIK 0001890152 · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Ordinary Shares · 2,477,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date. F5 · price: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date. F5 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date. F5 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date. F4 · ownership.nature: The securities are directly held by C2 Life Sciences LLC ("C2 Life"). The Advisor serves as the investment advisor to C2 Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:59 UTC | LianBio LIAN · Entity 9881 | ConversionSeries Seed Preferred Shares · Derivative | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042807 · doc4.xml · derivative · entry 11 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner LEV LB Holdings, LP · CIK 0001789443 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner C2 Life Sciences LLC · CIK 0001890152 · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Ordinary Shares · 2,923,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F6 · price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F6 · derivative.exercise_date: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F6 · derivative.expiration_date: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F3 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund, LP ("Perceptive Xontogeny"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment advisor to Perceptive Xontogeny and is an affiliate of the Advisor. Joseph Edelman is the managing member of the Advisor. The Venture Advisor, the Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:59 UTC | LianBio LIAN · Entity 9881 | ConversionSeries Seed Preferred Shares · Derivative | 2,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042807 · doc4.xml · derivative · entry 10 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner LEV LB Holdings, LP · CIK 0001789443 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner C2 Life Sciences LLC · CIK 0001890152 · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Ordinary Shares · 14,619,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F6 · price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F6 · derivative.exercise_date: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F6 · derivative.expiration_date: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F2 · ownership.nature: The securities are directly held by LEV LB Holdings, LP ("LEV LB"). LEV LB Holdings GP, LLC ("LEV LB LLC") is the manager of LEV LB. Mr. Edelman is the sole member of LEV LB LLC. LEV LB LLC and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:59 UTC | LianBio LIAN · Entity 9881 | ConversionSeries Seed Preferred Shares · Derivative | 2,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042807 · doc4.xml · derivative · entry 9 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner LEV LB Holdings, LP · CIK 0001789443 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner C2 Life Sciences LLC · CIK 0001890152 · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Ordinary Shares · 14,619,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F6 · price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F6 · derivative.exercise_date: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F6 · derivative.expiration_date: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:59 UTC | LianBio LIAN · Entity 9881 | ConversionSeries A Preferred Shares · Derivative | 635,369 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042807 · doc4.xml · derivative · entry 8 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner LEV LB Holdings, LP · CIK 0001789443 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner C2 Life Sciences LLC · CIK 0001890152 · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Ordinary Shares · 3,715,510 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date. F5 · price: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date. F5 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date. F5 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date. F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:59 UTC | LianBio LIAN · Entity 9881 | ConversionOrdinary Shares | 2,477,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 7 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner LEV LB Holdings, LP · CIK 0001789443 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner C2 Life Sciences LLC · CIK 0001890152 · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,477,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date. F4 · ownership.nature: The securities are directly held by C2 Life Sciences LLC ("C2 Life"). The Advisor serves as the investment advisor to C2 Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:59 UTC | LianBio LIAN · Entity 9881 | ConversionOrdinary Shares | 2,923,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 6 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner LEV LB Holdings, LP · CIK 0001789443 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner C2 Life Sciences LLC · CIK 0001890152 · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,330,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F3 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund, LP ("Perceptive Xontogeny"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment advisor to Perceptive Xontogeny and is an affiliate of the Advisor. Joseph Edelman is the managing member of the Advisor. The Venture Advisor, the Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:59 UTC | LianBio LIAN · Entity 9881 | ConversionOrdinary Shares | 14,619,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 5 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner LEV LB Holdings, LP · CIK 0001789443 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner C2 Life Sciences LLC · CIK 0001890152 · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,653,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F2 · ownership.nature: The securities are directly held by LEV LB Holdings, LP ("LEV LB"). LEV LB Holdings GP, LLC ("LEV LB LLC") is the manager of LEV LB. Mr. Edelman is the sole member of LEV LB LLC. LEV LB LLC and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:59 UTC | LianBio LIAN · Entity 9881 | ConversionOrdinary Shares | 14,619,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 4 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner LEV LB Holdings, LP · CIK 0001789443 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner C2 Life Sciences LLC · CIK 0001890152 · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 25,588,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date. F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:59 UTC | LianBio LIAN · Entity 9881 | ConversionOrdinary Shares | 3,715,510 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 3 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner LEV LB Holdings, LP · CIK 0001789443 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner C2 Life Sciences LLC · CIK 0001890152 · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,969,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date. F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 17:47 UTC | LianBio LIAN · Entity 9881 | PurchaseOrdinary Shares | 20,000 | $13.51 | $270,200.00 |
DisclosureSEC source: 0001062993-21-010295 · form4.xml · nonDerivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner LEV LB Holdings, LP · CIK 0001789443 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner C2 Life Sciences LLC · CIK 0001890152 · Director · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 27,858,895 F5 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.50 to $13.57, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range. F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 17:47 UTC | LianBio LIAN · Entity 9881 | PurchaseOrdinary Shares | 2,250,000 | $16.00 | $36,000,000.00 |
DisclosureSEC source: 0001062993-21-010295 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner LEV LB Holdings, LP · CIK 0001789443 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner C2 Life Sciences LLC · CIK 0001890152 · Director · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 27,838,895 F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 22:59 UTC | LianBio LIAN · Entity 9881 | PurchaseOrdinary Shares | 100,000 | $13.50 | $1,350,000.00 |
DisclosureSEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner LEV LB Holdings, LP · CIK 0001789443 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner C2 Life Sciences LLC · CIK 0001890152 · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,253,885 F7 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.79, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range. F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 22:59 UTC | LianBio LIAN · Entity 9881 | PurchaseOrdinary Shares | 120,000 | $15.50 | $1,860,000.00 |
DisclosureSEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner LEV LB Holdings, LP · CIK 0001789443 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner C2 Life Sciences LLC · CIK 0001890152 · 10% owner Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,153,885 F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| August 27, 2021 Filed Sep 1, 2021 01:31 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | GrantStock Option (Right to Buy) · Derivative | 25,291 | $0.00 Strike: $14.18 | $0.00 |
DisclosureSEC source: 0000899243-21-034678 · doc4.xml · derivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director EDELMAN JOSEPH · CIK 0001164426 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 25,291 Underlying: Common stock · 25,291 shares Expires 2031-08-26 F1 · derivative.exercise_date: The shares of common stock underlying this option will vest and become exercisable in 36 equal monthly installments beginning on August 27, 2021, subject to the Fred Callori's continuous service with the Issuer on each such date. F2 · ownership.nature: Consists of a proportionate interest in stock options awarded to Mr. Callori in connection with his role as a member of the Issuer's Board of Directors. Mr. Callori serves as a partner of Perceptive Xontogeny Venture Funds. Perceptive Advisors LLC may be deemed to have an indirect pecuniary interest in the securities reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Callori's board service through a partial management fee offset. F3 · ownership.nature: Each of the Reporting Persons disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 00:20 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | PurchaseCommon Stock | 34,951 | $14.60 | $510,284.60 |
DisclosureSEC source: 0001062993-21-001115 · form4.xml · nonDerivative · entry 6 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,299,751 F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F7 · price: These shares were purchased in multiple transactions at prices ranging from $14.17 to $15.20, inclusive. F8 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the ???Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 00:20 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | PurchaseCommon Stock | 64,730 | $13.80 | $893,274.00 |
DisclosureSEC source: 0001062993-21-001115 · form4.xml · nonDerivative · entry 5 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,264,800 F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F6 · price: These shares were purchased in multiple transactions at prices ranging from $13.17 to $14.16, inclusive. F8 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the ???Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:37 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | ConversionSeries B Preferred Stock · Derivative | 1,770,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-001012 · form4.xml · derivative · entry 12 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,770,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F2 · price: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F2 · derivative.exercise_date: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F2 · derivative.expiration_date: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F5 · ownership.nature: The securities are directly held by PX Venture (A), LLC. The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:37 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | ConversionSeries B Preferred Stock · Derivative | 2,857,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-001012 · form4.xml · derivative · entry 11 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,857,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F2 · price: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F2 · derivative.exercise_date: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F2 · derivative.expiration_date: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F4 · ownership.nature: The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:37 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | ConversionSeries B Preferred Stock · Derivative | 2,857,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-001012 · form4.xml · derivative · entry 10 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,857,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F2 · price: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F2 · derivative.exercise_date: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F2 · derivative.expiration_date: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:37 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | ConversionSeries A Preferred Stock · Derivative | 2,941,769 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-001012 · form4.xml · derivative · entry 9 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,941,769 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F1 · price: Each share of the Issuer's Series A preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F4 · ownership.nature: The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:37 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | ConversionSeries A Preferred Stock · Derivative | 2,941,769 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-001012 · form4.xml · derivative · entry 8 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,941,769 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F1 · price: Each share of the Issuer's Series A preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:37 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | PurchaseCommon Stock | 1,250,000 | $16.00 | $20,000,000.00 |
DisclosureSEC source: 0001062993-21-001012 · form4.xml · nonDerivative · entry 6 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,049,564 F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:37 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | ConversionCommon Stock | 1,770,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-001012 · form4.xml · nonDerivative · entry 5 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,770,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F5 · ownership.nature: The securities are directly held by PX Venture (A), LLC. The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:37 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | ConversionCommon Stock | 2,857,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-001012 · form4.xml · nonDerivative · entry 4 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,799,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F4 · ownership.nature: The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:37 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | ConversionCommon Stock | 2,857,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-001012 · form4.xml · nonDerivative · entry 3 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,799,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date. F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:37 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | ConversionCommon Stock | 2,941,769 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-001012 · form4.xml · nonDerivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,941,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F4 · ownership.nature: The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:37 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | ConversionCommon Stock | 2,941,769 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-001012 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,941,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date. F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 00:20 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | PurchaseCommon Stock | 1,771 | $13.10 | $23,200.10 |
DisclosureSEC source: 0001062993-21-001115 · form4.xml · nonDerivative · entry 4 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner Xontogeny, LLC · CIK 0001844296 · Director · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,200,070 F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. F5 · price: These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.10, inclusive. F8 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the ???Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.